Our Mission
Our Mission is to improve the lives of patients suffering from difficult to treat cancers, with a focus on pancreatic cancer through novel therapies that prime and boost their immune response and improve the performance of their cancer treatment, enabling them to live longer.
About Us
Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immunomodulator. IMM-101 induces a broad immune response, modulating the innate and adaptive immune systems with a potential to complement existing therapies, including targeted immunotherapies and cytotoxics. IMM-101 has the potential to work in difficult-to-treat tumours, including those that have been considered immunologically ‘cold’.
Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine.
Latest from Immodulon
Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer
Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal trial in...
Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer
Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the Board Gertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive Officer Peter Greaney, formerly at ADC Therapeutics and Celgene, appointed as Chief Business Officer...
Immodulon strengthens Board of Directors with two industry veteran appointments
Seasoned global biopharmaceutical executives add significant clinical and commercial experience to Immodulon Dr. Selwyn Ho and Gertjan Bartlema will join the Board with immediate effect Uxbridge, UK – 14 June 2022 – Immodulon Therapeutics Limited, the immuno-oncology...